"Black Box" Will Not Deter Off-Label Zyprexa Use In Dementia Patients, Lilly Says

The company points to the lack of indicated alternatives for treating dementia-related psychosis as one reason why psychiatrists will continue to prescribe atypical antipsychotics despite a new "black box" warning on mortality in that patient population. First quarter U.S. Zyprexa sales fell 17% compared to the same period in 2004.